UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bladder preservation in the treatment of muscle‐invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy

BJU international, 2013-07, Vol.112 (1), p.13-25

2013

Volltextzugriff (PDF)

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

The New England journal of medicine, 2021-11, Vol.385 (20), p.1856-1867

2021

Volltextzugriff (PDF)

A Novel Risk Stratification to Predict Local-Regional Failures in Urothelial Carcinoma of the Bladder After Radical Cystectomy

International journal of radiation oncology, biology, physics, 2013, Vol.85 (1), p.81-88

2013

Volltextzugriff (PDF)

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

The lancet oncology, 2017-11, Vol.18 (11), p.1483-1492

2017

Volltextzugriff (PDF)

Occult Pelvic Lymph Node Involvement in Bladder Cancer: Implications for Definitive Radiation

International journal of radiation oncology, biology, physics, 2014-03, Vol.88 (3), p.603-610

2014

Volltextzugriff (PDF)

Bladder Cancer Patterns of Pelvic Failure: Implications for Adjuvant Radiation Therapy

International journal of radiation oncology, biology, physics, 2013-02, Vol.85 (2), p.363-369

2013

Volltextzugriff (PDF)

Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database

Cancer epidemiology, biomarkers & prevention, 2015-01, Vol.24 (1), p.303-307

2015

Volltextzugriff (PDF)

Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications

Clinical cancer research, 2010-02, Vol.16 (3), p.778-783

2010

Volltextzugriff (PDF)

Reply to P.-H. Luo et al

Journal of clinical oncology, 2024-05, Vol.42 (13), p.1596-1598

2024

Volltextzugriff (PDF)

Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective

Seminars in oncology, 2014-02, Vol.41, p.S1-S16

2014

Volltextzugriff (PDF)

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

The Lancet (British edition), 2024-04, Vol.403 (10434), p.1341-1350

2024

Volltextzugriff (PDF)

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Journal of clinical oncology, 2023-12, Vol.41 (36), p.5505-5511

2023

Volltextzugriff (PDF)

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment

Journal of clinical oncology, 2015-01, Vol.33 (3), p.278-284

2015

Volltextzugriff (PDF)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas

Diabetes care, 2014-07, Vol.37 (7), p.1910-1917

2014

Volltextzugriff (PDF)

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2024-10, Vol.404 (10460), p.1321-1332

2024

Volltextzugriff (PDF)

The Molecular Biology of Renal Cell Carcinoma

Seminars in oncology, 2013-08, Vol.40 (4), p.421-428

2013

Volltextzugriff (PDF)

Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer

International journal of gynecological cancer, 2020-07, Vol.30 (7), p.1034-1042

2020

Volltextzugriff (PDF)

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment

Journal of clinical oncology, 2017-01, Vol.35 (2), p.139-140

2017

Volltextzugriff (PDF)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma

Cancer management and research, 2015-01, Vol.7 (default), p.65-73

2015

Volltextzugriff (PDF)

Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: A case study

Cancer biology & therapy, 2014-06, Vol.15 (6), p.683-687

2014

Volltextzugriff (PDF)

MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib

American journal of roentgenology (1976), 2013-01, Vol.200 (1), p.120-126

2013

Volltextzugriff (PDF)

The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Current oncology reports, 2010, Vol.12 (1), p.22-25

2010

Volltextzugriff (PDF)

On the importance of heterogeneity in meta-analysis

Clinical trials (London, England), 2009-10, Vol.6 (5), p.443-444

2009

Volltextzugriff (PDF)

1 – 25 von 170

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(142)

Publikationsform

Artikel
(169)
Bücher
(1)

Sprache

Englisch
(170)

Erscheinungsjahr

n.n

Thema

Science & Technology
(112)
Life Sciences & Biomedicine
(110)
Humans
(100)
Female
(59)
Male
(51)
Middle Aged
(43)
Adult
(42)
Biological And Medical Sciences
(41)
Medical Sciences
(37)
Oncology
(34)
Aged
(29)
Psychiatry
(25)
Schizophrenia
(22)
Adolescent
(21)
Chemotherapy
(17)
Psychology. Psychoanalysis. Psychiatry
(17)
Animals
(16)
Psychopathology. Psychiatry
(16)
Hematology, Oncology And Palliative Medicine
(14)
Adult And Adolescent Clinical Studies
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Bladder preservation in the treatment of muscle‐invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

A Novel Risk Stratification to Predict Local-Regional Failures in Urothelial Carcinoma of the Bladder After Radical Cystectomy

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Occult Pelvic Lymph Node Involvement in Bladder Cancer: Implications for Definitive Radiation

Bladder Cancer Patterns of Pelvic Failure: Implications for Adjuvant Radiation Therapy

Validation of a coding algorithm to identify bladder cancer and distinguish stage in an electronic medical records database

Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications

Reply to P.-H. Luo et al

Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

The Molecular Biology of Renal Cell Carcinoma

Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma

Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: A case study

MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib

The Expanding Role of Bevacizumab in the Treatment of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

On the importance of heterogeneity in meta-analysis

Suchergebnisse filtern